La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

ANI Pharmaceuticals Croissance future

Future contrôle des critères 4/6

ANI Pharmaceuticals devrait augmenter ses bénéfices et ses revenus de 35.4% et de 9.1% par an respectivement, tandis que le BPA devrait croître de croître de 34.7% par an.

Informations clés

35.4%

Taux de croissance des bénéfices

34.7%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	23.6%
Taux de croissance des recettes	9.3%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	19 Sep 2024

Mises à jour récentes de la croissance future

Recent updates

ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028

Aug 02

Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

Jun 10

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

Jun 10

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

Feb 17

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Nov 15

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Sep 22

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Feb 22

We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt

Oct 28

ANI Pharma launches generic Prochlorperazine maleate tablets

Aug 29

ANI Pharmaceuticals' generic dexamethasone tablets get FDA approval

Aug 16

ANI Pharmaceuticals Q2 2022 Earnings Preview

Aug 05

Prévisions de croissance des bénéfices et des revenus

NasdaqGM:ANIP - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	757	66	130	242	4
12/31/2025	714	41	80	193	4
12/31/2024	591	27	29	120	4
6/30/2024	539	23	94	113	N/A
3/31/2024	517	31	95	116	N/A
12/31/2023	487	15	100	119	N/A
9/30/2023	449	10	53	70	N/A
6/30/2023	401	-8	19	41	N/A
3/31/2023	359	-28	-7	9	N/A
12/31/2022	316	-50	-48	-31	N/A
9/30/2022	283	-69	-53	-39	N/A
6/30/2022	251	-65	-52	-48	N/A
3/31/2022	226	-63	-61	-36	N/A
12/31/2021	216	-43	-20	3	N/A
9/30/2021	212	-22	-16	10	N/A
6/30/2021	213	-17	-17	14	N/A
3/31/2021	213	-15	23	34	N/A
12/31/2020	208	-23	-53	15	N/A
9/30/2020	199	-24	-42	26	N/A
6/30/2020	198	-20	-15	49	N/A
3/31/2020	203	-1	-32	33	N/A
12/31/2019	207	6	18	46	N/A
9/30/2019	216	16	41	68	N/A
6/30/2019	215	17	28	55	N/A
3/31/2019	208	14	30	58	N/A
12/31/2018	202	15	56	67	N/A
9/30/2018	192	0	-4	56	N/A
6/30/2018	189	0	3	64	N/A
3/31/2018	187	0	N/A	56	N/A
12/31/2017	177	-1	N/A	39	N/A
9/30/2017	168	7	N/A	36	N/A
6/30/2017	158	5	N/A	20	N/A
3/31/2017	145	4	N/A	23	N/A
12/31/2016	129	4	N/A	27	N/A
9/30/2016	108	8	N/A	20	N/A
6/30/2016	90	10	N/A	29	N/A
3/31/2016	78	12	N/A	27	N/A
12/31/2015	76	15	N/A	17	N/A
9/30/2015	79	33	N/A	23	N/A
6/30/2015	77	35	N/A	17	N/A
3/31/2015	64	30	N/A	18	N/A
12/31/2014	56	29	N/A	22	N/A
9/30/2014	45	11	N/A	8	N/A
6/30/2014	36	5	N/A	3	N/A
3/31/2014	35	1	N/A	0	N/A
12/31/2013	30	-5	N/A	-5	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de ANIP ( 35.4% par an) est supérieure au taux d'épargne ( 2.5% ).

Bénéfices vs marché: Les bénéfices de ANIP ( 35.4% par an) devraient croître plus rapidement que le marché US ( 15.2% par an).

Croissance élevée des bénéfices: Les bénéfices de ANIP devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de ANIP ( 9.1% par an) devrait croître plus rapidement que le marché US ( 8.7% par an).

Croissance élevée des revenus: Le chiffre d'affaires de ANIP ( 5.6% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de ANIP devrait être élevé dans 3 ans

ANI Pharmaceuticals Croissance future

Future contrôle des critères 4/6

Informations clés

Mises à jour récentes de la croissance future

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2024

ANI Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

Consensus EPS estimates increase by 27%

Price target increased by 7.5% to US$75.50

ANI Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2023

Recent updates

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) completed the acquisition of Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.

Alimera Sciences, Inc. Takes Legal Action Against ANI Pharmaceuticals, Inc. to Enforce Merger Agreement

Alimera Sciences, Inc. Takes Legal Action Against ANI Pharmaceuticals, Inc. to Enforce Merger Agreement

There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues

ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem

Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2024

ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028

ANI Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of L-Glutamine Oral Powder

ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell 3000E Value Index

ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) signed a definitive agreement to acquire Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others for approximately $300 million.

Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

Head of R&D notifies of intention to sell stock

President recently sold US$1.1m worth of stock

President notifies of intention to sell stock

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

ANI Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 10, 2024

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension

ANI Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

ANI Pharmaceuticals, Inc. Announces the Launch of Levofloxacin Oral Solution, USP

Consensus EPS estimates increase by 27%

Independent Director notifies of intention to sell stock

Price target increased by 7.5% to US$75.50

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ANI Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

ANI Pharmaceuticals, Inc. to Report Second Half, 2023 Results on Feb 29, 2024

ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP

Head of R&D notifies of intention to sell stock

Head of R&D notifies of intention to sell stock

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Head of Rare Disease recently sold US$157k worth of stock

New minor risk - Earnings quality

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2023

New major risk - Revenue and earnings growth

ANI Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Head of R&D notifies of intention to sell stock

Ani Pharmaceuticals Announces Fda Approval and Commercial Availability of New 1-Ml Vial Size of Purified Cortrophin®? Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Head of R&D notifies of intention to sell stock

Ani Pharmaceuticals Announces the Fda Approval and Launch of Estradiol Gel, 0.1%

ANI Pharmaceuticals, Inc. Announces Board Changes

Head of R&D notifies of intention to sell stock

President recently sold US$3.3m worth of stock

President notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023

ANI Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New minor risk - Profitability

Head of R&D notifies of intention to sell stock

Price target increased by 12% to US$55.00

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $75.000033 million.

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Raises Revenue Guidance for Full Year 2023

Consensus EPS estimates fall by 42%, revenue upgraded

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 7.7% to US$46.60

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Levocarnitine Tablets USP

ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP